Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 11/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 11/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 11/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 9/20 | 0.40 |
| ▸ | CCR5 | P51681 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600865 | 1.00 | CHRM4 (0.40) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL10190325 | 0.89 | CHRM4 (0.44) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL601456 | 0.86 | CHRM4 (0.40) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL601457 | 0.86 | CHRM4 (0.40) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL603224 | 0.84 | PIK3CA (0.33) | — | |
| SCHEMBL602337 | 0.84 | PIK3CA (0.33) | — | |
| SCHEMBL602338 | 0.84 | PIK3CA (0.33) | — | |
| SCHEMBL602394 | 0.81 | CHRM4 (0.54) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL602393 | 0.81 | CHRM4 (0.54) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL602860 | 0.81 | CHRM4 (0.54) | CHRM4CHRM5CHRM1CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996188-B1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2013-05-15 | — | — | EP | disclosed |
| US-20120309789-A1 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED | 2012-12-06 | — | — | US | disclosed |
| US-20120041027-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED | 2012-02-16 | — | — | US | disclosed |
| US-20100190825-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | COOPER DAVID GWYN | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190825-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | CHRM4 3/4885CHRM5 4/4885CHRM1 1/4885 |
| US-20120041027-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | CHRM4 3/4885CHRM5 4/4885CHRM1 1/4885 |
| US-20120309789-A1 | Compounds which have activity at M1 receptor and their uses in medicine | CHRM1, CHRM2, CHRM5 | CHRM4 4/4885CHRM5 3/4885CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.